Sophiris Bio Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
48,149.00
22,695.00
8,381.00
29,001.00
25,844.00
12,539
Total Accounts Receivable
48.00
16.00
8.00
128.00
13.00
-
Other Current Assets
3,598.00
2,825.00
467.00
846.00
999.00
656
Total Current Assets
51,795.00
25,536.00
8,856.00
29,975.00
26,856.00
13,195
Net Property, Plant & Equipment
78.00
36.00
17.00
4.00
2.00
4
Other Assets
19.00
19.00
19.00
19.00
19.00
-
Total Assets
51,892.00
25,591.00
8,892.00
29,998.00
26,877.00
13,199
ST Debt & Current Portion LT Debt
6,877.00
598.00
1,771.00
-
372.00
Accounts Payable
1,470.00
-
-
-
-
Other Current Liabilities
2,181.00
4,940.00
1,475.00
2,221.00
2,331.00
Total Current Liabilities
10,528.00
5,538.00
3,246.00
2,221.00
2,703.00
Long-Term Debt
-
5,343.00
3,572.00
-
6,435.00
Other Liabilities
1,085.00
22.00
168.00
13,453.00
10,089.00
Total Liabilities
11,613.00
10,903.00
6,986.00
15,674.00
19,227.00
Common Equity (Total)
40,279.00
14,688.00
1,906.00
14,324.00
7,650.00
Total Shareholders' Equity
40,279.00
14,688.00
1,906.00
14,324.00
7,650.00
Total Equity
40,279.00
14,688.00
1,906.00
14,324.00
7,650.00
Liabilities & Shareholders' Equity
51,892.00
25,591.00
8,892.00
29,998.00
26,877.00

About Sophiris Bio

View Profile
Address
1258 Prospect Street
La Jolla California 92037
United States
Employees -
Website http://www.sophirisbio.com
Updated 07/08/2019
Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. It is currently developing PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L.